[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391518":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":99,"locations":105,"responsibleParty":124,"collaborators":10,"id":128,"slug":129,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":10,"eligibilityCriteria":133,"healthyVolunteers":130,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":140,"studyType":141,"phases":10,"briefSummary":142,"conditions":143,"keywords":10,"overallStatus":108,"whyStopped":10,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Hospital Vall d'Hebron","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group",null,"Patients with unresectable perihilar cholangiocarcinoma (pCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases",[13,14],"Drug: Neoadjuvant Chemo-radiotherapy","Procedure: Liver Transplantation",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DRUG","Neoadjuvant Chemo-radiotherapy","Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg\u002Fm2 bid).Thereafter, gemcitabine iv (1000mg\u002Fm2) plus cisplatin iv (25mg\u002Fm2) will be administered the day 1 and 8 every 21 days until transplant.",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"PROCEDURE","Liver Transplantation","If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.",[9],[27,31,34,37,40,43,46,49,52,55,58,61,64,67,71,73,76,78,81,84,87,90,93,96],{"name":28,"affiliation":29,"role":30},"Sonia Pascual-Bartolomé","HOSPITAL GENERAL UNIVERSITARIO, ALICANTE","STUDY_CHAIR",{"name":32,"affiliation":33,"role":30},"Carmelo Loinaz-Segurola","HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, MADRID",{"name":35,"affiliation":36,"role":30},"José María Álamo-Martinez","HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLA",{"name":38,"affiliation":39,"role":30},"José Luis Lucena de la Poza","Hospital Universitario Puerta de Hierro Majadahonda",{"name":41,"affiliation":42,"role":30},"Arturo Colon-Rodríguez","HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARANON, MADRID",{"name":44,"affiliation":45,"role":30},"Diego López-Segarra","COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ",{"name":47,"affiliation":48,"role":30},"Yilliam Fundora-Suárez","Hospital Clinic of Barcelona",{"name":50,"affiliation":51,"role":30},"Eva Montalvá-Orón","Hospital Universitario La Fe",{"name":53,"affiliation":54,"role":30},"Juan Andrés Echeverri-Cifuentes","HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, SANTANDER",{"name":56,"affiliation":57,"role":30},"María Teresa Salcedo-Allende","HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA",{"name":59,"affiliation":60,"role":30},"José Antonio Gracia Solanas","HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, ZARAGOZA",{"name":62,"affiliation":63,"role":30},"Adriá Rosat-Rodrigo","HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE LA CANDELARIA, TENERIFE",{"name":65,"affiliation":66,"role":30},"Victor Lopez-Lopez","Hospital Universitario Virgen de la Arrixaca",{"name":68,"affiliation":69,"role":70},"Laura Lladó-Garrida","HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA","STUDY_DIRECTOR",{"name":72,"affiliation":48,"role":70},"María Teresa Macarulla-Mercadé",{"name":74,"affiliation":75,"role":70},"Begoña Navalpotro-Yagüe","HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA",{"name":77,"affiliation":75,"role":30},"Jaume Capdevila",{"name":79,"affiliation":80,"role":30},"Julio Santoyo","HOSPITAL REGIONAL UNIVERSITARIO DE MALAGA",{"name":82,"affiliation":83,"role":30},"Manuel Durán Martínez","HOSPITAL UNIVERSITARIO REINA SOFIA DE CÓRDOBA",{"name":85,"affiliation":86,"role":30},"Natalia Zambudio","Hospital Virgen de las Nieves (Granada)",{"name":88,"affiliation":89,"role":30},"Mikel Gastaka","Hospital Universitario de Cruces",{"name":91,"affiliation":92,"role":30},"Manuel Abradelo","Hospital Universitario de Toledo",{"name":94,"affiliation":95,"role":30},"Dora Gómez-Pasantes","Complejo Hospitalario Universitario, A Coruña",{"name":97,"affiliation":98,"role":30},"Carmen Bernardo","Hospital Universitario Central de Asturias",[100],{"name":101,"role":102,"phone":103,"phoneExt":10,"email":104},"CRISTINA DOPAZO, MD\u002FPhD","CONTACT","+34932746113","cristina.dopazo@vallhebron.cat",[106],{"facility":107,"status":108,"city":109,"state":109,"zip":110,"country":111,"countryCode":112,"cosmosGeoPoint":113,"geoPoint":118,"contacts":119},"Department of HPB Surgery and Transplants, Hospital Vall d´Hebron","RECRUITING","Barcelona","08035","Spain","ES",{"type":114,"coordinates":115},"Point",[116,117],2.15899,41.38879,{"lat":117,"lon":116},[120],{"name":121,"role":102,"phone":122,"phoneExt":123,"email":104},"Cristina Dopazo, PhD\u002FMD","+34932746000","6113",{"type":125,"investigatorFullName":126,"investigatorTitle":127,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Cristina Dopazo Taboada","Consultant Surgeon","100391518","liver-transplant-combined-with-neoadjuvant-chemo-radiotherapy-in-the-treatment-of-unresectable-perihilar-cholangiocarcinoma-a-prospective-multicenter-study-100391518",false,"NCT04378023","Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study.","Inclusion Criteria:\n\n* Willing and able to provide written consent form\n* Age ≤ 70 years-old\n* ECOG 0 or 1\n* Unresectable hCCA ≤3cm in radial diameter\n\nExclusion Criteria:\n\n* Those patients who have received chemotherapy or radiotherapy previously out of protocol\n* Liver, extrahepatic or lymph node metastases\n* Previous intent of surgical resection or percutaneous biopsy\n* Previous or concurrent cancer that is different in primary site or histology from adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively treated 5 years prior to entry is permitted.\n* Infection no controlled","ALL","18 Years","70 Years",{"count":138,"type":139},34,"ESTIMATED","5 Years","OBSERVATIONAL","A prospective multicentre study which includes patients ≤ 70 years-old diagnosed of unresectable perihilar cholangiocarcinoma (pCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radiochemotherapy will be performed in this selected group.\n\nThe primary endpoint will be overall survival at 1, 3, and 5 years post-transplant. The secondary endpoints will be: 1) recurrence-free survival at 1, 3 and 5 years post-transplant; 2) intention-to-treat survival of all patients included in the study at 1,3 and 5 years; 3) the rate of patients included in the study who are finally transplanted.",[144],"Unresectable Cholangiocarcinoma","2026-05-21",{"date":147,"type":148},"2026-05-26","ACTUAL",{"date":150,"type":148},"2020-04-24",{"date":152,"type":139},"2027-06-01",{"name":5,"class":6},1]